Research ArticleOriginal Article
Open Access

Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy

Heliang Wu, Yi Wang, Yulin Lin, Ru Ma, Xuemei Du, Yandong Su, Rui Yang, Zhiran Yang, Xinli Liang, Yinguang Zhang, Xiaoqing Liang, Zhonghe Ji, Chunning Lai, Yajing Huang and Yan Li
Cancer Biology & Medicine November 2024, 20240218; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0218

References

  1. 1.↵
    2. Sung H,
    3. Ferlay J,
    4. Siegel RL,
    5. Laversanne M,
    6. Soerjomataram I,
    7. Jemal A, et al.
    Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.
    OpenUrlCrossRefPubMed
  2. 2.
    2. Huang J,
    3. Chan SC,
    4. Pang WS,
    5. Chow SH,
    6. Lok V,
    7. Zhang L, et al.
    Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023; 18: 792–802.
    OpenUrlPubMed
  3. 3.
    2. Yang R,
    3. Su YD,
    4. Ma R,
    5. Li Y.
    Clinical epidemiology of peritoneal metastases in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023; 49: 173–8.
    OpenUrlPubMed
  4. 4.↵
    2. Kusamura S,
    3. Kepenekian V,
    4. Villeneuve L,
    5. Lurvink RJ,
    6. Govaerts K,
    7. De Hingh IHJT, et al.
    Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021; 47: 36–59.
    OpenUrlPubMed
  5. 5.↵
    2. Li CY,
    3. Alexander HR Jr..
    Peritoneal metastases from malignant mesothelioma. Surg Oncol Clin N Am. 2018; 27: 539–49.
    OpenUrlPubMed
  6. 6.↵
    2. Su YD,
    3. Yang ZR,
    4. Li XB,
    5. Yu Y,
    6. Du XM,
    7. Li Y.
    Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China. Int J Hyperthermia. 2022; 39: 706–12.
    OpenUrlPubMed
  7. 7.↵
    2. Scoville SD,
    3. Freud AG,
    4. Caligiuri MA.
    Modeling human natural killer cell development in the era of innate lymphoid cells. Front Immunol. 2017; 8: 360.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Laskowski TJ,
    3. Biederstädt A,
    4. Rezvani K.
    Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022; 22: 557–75.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Wu SY,
    3. Fu T,
    4. Jiang YZ,
    5. Shao ZM.
    Natural killer cells in cancer biology and therapy. Mol Cancer. 2020; 19: 120.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Sivori S,
    3. Vacca P,
    4. Del Zotto G,
    5. Munari E,
    6. Mingari MC,
    7. Moretta L.
    Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019; 16: 430–41.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Xiao J,
    3. Zhang T,
    4. Gao F,
    5. Zhou Z,
    6. Shu G,
    7. Zou Y, et al.
    Natural killer cells: a promising kit in the adoptive cell therapy toolbox. Cancers (Basel). 2022; 14: 5657.
    OpenUrlPubMed
  12. 12.↵
    2. Cao B,
    3. Liu M,
    4. Huang J,
    5. Zhou J,
    6. Li J,
    7. Lian H, et al.
    Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021; 17: 3850–61.
    OpenUrlPubMed
  13. 13.
    2. Zhang Q,
    3. Zhang H,
    4. Ding J,
    5. Liu H,
    6. Li H,
    7. Li H, et al.
    Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res. 2018; 2018: 4263520.
  14. 14.
    2. Klapdor R,
    3. Wang S,
    4. Morgan M,
    5. Dörk T,
    6. Hacker U,
    7. Hillemanns P, et al.
    Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int J Mol Sci. 2019; 20: 660.
    OpenUrlCrossRefPubMed
  15. 15.
    2. Lee YE,
    3. Ju A,
    4. Choi HW,
    5. Kim JC,
    6. Kim EE,
    7. Kim TS, et al.
    Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release. 2020; 326: 310–23.
    OpenUrlPubMed
  16. 16.↵
    2. Baghery Saghchy Khorasani A,
    3. Yousefi AM,
    4. Bashash D.
    CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. Int Immunopharmacol. 2022; 110: 109041.
  17. 17.↵
    2. Yang ZR,
    3. Chen ZG,
    4. Ji ZH,
    5. Lin YL,
    6. Zhang J,
    7. Ma R, et al.
    Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma. Exp Anim. 2021; 70: 225–35.
    OpenUrlPubMed
  18. 18.↵
    2. Ren C,
    3. Li M,
    4. Zheng Y,
    5. Cai B,
    6. Du W,
    7. Zhang H, et al.
    Single-cell RNA-seq reveals altered NK cell subsets and reduced levels of cytotoxic molecules in patients with ankylosing spondylitis. J Cell Mol Med. 2022; 26: 1071–82.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Vahedi F,
    3. Nham T,
    4. Poznanski SM,
    5. Chew MV,
    6. Shenouda MM,
    7. Lee D, et al.
    Ex vivo expanded human NK cells survive and proliferate in humanized mice with autologous human immune cells. Sci Rep. 2017; 7: 12083.
  20. 20.↵
    2. Ma R,
    3. Lin YL,
    4. Li XB,
    5. Yan FC,
    6. Xu HB,
    7. Peng Z, et al.
    Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study. Diagn Pathol. 2021; 16: 116.
    OpenUrlPubMed
  21. 21.↵
    2. Wu HL,
    3. Yang ZR,
    4. Su YD,
    5. Ma R,
    6. Du XM,
    7. Gao Y, et al.
    Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases. World J Surg Oncol. 2022; 20: 350.
    OpenUrlPubMed
  22. 22.↵
    2. Marin ND,
    3. Krasnick BA,
    4. Becker-Hapak M,
    5. Conant L,
    6. Goedegebuure SP,
    7. Berrien-Elliott MM, et al.
    Memory-like differentiation enhances NK cell responses to melanoma. Clin Cancer Res. 2021; 27: 4859–69.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Chen M,
    3. Li Y,
    4. Wu Y,
    5. Xie S,
    6. Ma J,
    7. Yue J, et al.
    Anti-tumor activity of expanded PBMC-derived NK cells by feeder-free protocol in ovarian cancer. Cancers (Basel). 2021; 13: 5866.
    OpenUrlPubMed
  24. 24.↵
    2. Hoogstad-van Evert JS,
    3. Cany J,
    4. van den Brand D,
    5. Oudenampsen M,
    6. Brock R,
    7. Torensma R, et al.
    Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. Oncoimmunology. 2017; 6: e1320630.
  25. 25.↵
    2. McGranahan N,
    3. Swanton C.
    Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017; 168: 613–28.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Voron T,
    3. Colussi O,
    4. Marcheteau E,
    5. Pernot S,
    6. Nizard M,
    7. Pointet AL, et al.
    VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015; 212: 139–48.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Sharma P,
    3. Hu-Lieskovan S,
    4. Wargo JA,
    5. Ribas A.
    Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017; 168: 707–23.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Fais S,
    3. Overholtzer M.
    Cell-in-cell phenomena in cancer. Nat Rev Cancer. 2018; 18: 758–66.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Su Y,
    3. Huang H,
    4. Luo T,
    5. Zheng Y,
    6. Fan J,
    7. Ren H, et al.
    Cell-in-cell structure mediates in-cell killing suppressed by CD44. Cell Discov. 2022; 8: 35.
    OpenUrlPubMed
  30. 30.↵
    2. Zhang Q,
    3. Bi J,
    4. Zheng X,
    5. Chen Y,
    6. Wang H,
    7. Wu W, et al.
    Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018; 19: 723–32.
    OpenUrlCrossRefPubMed
  31. 31.
    2. Terrén I,
    3. Orrantia A,
    4. Vitallé J,
    5. Zenarruzabeitia O,
    6. Borrego F.
    NK cell metabolism and tumor microenvironment. Front Immunol. 2019; 10: 2278.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Wang D,
    3. Wei H.
    Natural killer cells in tumor immunotherapy. Cancer Biol Med. 2023; 20: 539–44.
    OpenUrlFREE Full Text
  33. 33.↵
    2. Aggarwal V,
    3. Workman CJ,
    4. Vignali DAA.
    LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023; 24: 1415–22.
    OpenUrlPubMed
  34. 34.↵
    2. Fuentes-Antrás J,
    3. Provencio M,
    4. Díaz-Rubio E.
    Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev. 2018; 70: 16–21.
    OpenUrlPubMed
  35. 35.↵
    2. Kato S,
    3. Goodman A,
    4. Walavalkar V,
    5. Barkauskas DA,
    6. Sharabi A,
    7. Kurzrock R.
    Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017; 23: 4242–50.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords